MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• The MET receptor tyrosine kinase plays a crucial role in various cancers, including non-small cell lung cancer (NSCLC).
• MET alterations, such as exon 14 mutations and amplification, are key drivers in a subset of NSCLC patients.
• Targeting MET with inhibitors like capmatinib is a strategy to overcome resistance and improve treatment outcomes.

Purpose of the Study:

• To investigate the efficacy of capmatinib, a MET inhibitor, in combination with radiation therapy.
• To evaluate this combination in preclinical models of non-small cell lung cancer (NSCLC) harboring MET exon 14 mutations or MET amplification.

Main Methods:

• In vitro studies assessed cell proliferation, colony formation, MET signaling, apoptosis, and DNA damage repair.
• In vivo experiments utilized cell line and patient-derived xenograft models to evaluate tumor response.
• Immunohistochemistry was employed to confirm molecular changes and treatment effects.

Main Results:

• Capmatinib demonstrated radiosensitization in MET-altered NSCLC cell lines, enhancing radiation's effect on clonogenic survival.
• The combination inhibited DNA double-strand break repair, evidenced by prolonged γH2AX expression.
• In vivo, capmatinib plus radiation significantly delayed tumor growth compared to monotherapy or control.
• Immunohistochemistry confirmed MET pathway inhibition and reduced tumor proliferation markers.

Conclusions:

• Inhibition of the MET receptor with capmatinib potentiates the anti-tumor effects of radiation therapy.
• This combination strategy shows significant promise for treating non-small cell lung cancer (NSCLC) with MET exon 14 mutations or MET amplification.